

(Crysvita) Burosumab-twza Infusion orders

Date:

PATIENT INFORMATION	
Name:	DOB: SEX: M 🗆 F 🗆
ICD-10 code (required):	ICD-10 description:
□NKDA Allergies:	Weight lbs/kg:
REFERRAL STATUS	
New Referral Referral Renewal Medication/Order Change Benefits Verification Only Discontinuation Order	
PHYSICIAN INFORMATION	
Referral Coordinator Name:	Referral Coordinator Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
DIAGNOSIS (and ICD 10 code) XLH: (familial hypophosphatemia) ICD-10 Code: E83.31 TIO: other adult osteomalacia ICD-10 Code: M83.8 Other disorders of phosphorus metabolism ICD-10 Code: E83.39	Burosumab-twza ORDERS Indication Pediatric XLH (6 months and older) Adult XLH Pediatric TIO 2 years and older Adult TIO *Adult TIO *Adult TIO
NOTE	Medication(check one)
 List Tried & Failed Therapies, including duration of treatment: a a **Referring physician is responsible for monitoring and reviewing the following labs prior to treatment: Fasting phosphorus level prior to each dose for first 3 doses and administer only if below ULN Fasting phosphorus level 2-4 weeks after dose modifications If dose adjustments are needed, new order must be sent by provider based on PI dose calculations 	 Crysvita less than 10 kg Crysvita greater than 10 kg Crysvita Dosing 1 mg/kg SQ rounded to the nearest 1 mg max 90 mg 0.8 mg/kg SQ rounded to the nearest 10 mg max 90 mg 1 mg/kg SQ rounded to the nearest 10 mg max 90 mg 0.4 mg/kg SQ rounded to the nearest 10 mg 2 mg/kg not to exceed 180 mg 0.5 mg/kg not to exceed 180 mg 0.5 mg/kg (dose may be increased up to 2mg/kg not to exceed 180mg administered every 2weeks) Frequency Every 2 weeks Every 4 weeks Every 4 weeks Every 4 weeks
	Refills*: None X6 months X1 year Other:

REQUIRED DOCUMENTATION:

- □ This signed order form by the provider
- □ Patient demographics AND insurance information
- □ Clinical/Progress notes supporting primary diagnosis
- Documentation that pt has stopped phos meds and Vit D
- □ Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment

ORDERING PROVIDER

Signature X

Date____

Provider _____ Fax _____